Revolution Medicines Chief Development Officer Sells 341 Shares for Tax Withholding

Insider Filing Analysis: Revolution Medicines, Inc. (NASDAQ: RVMD)

Overview

On September 18, 2026, Alan B. Sandler, Chief Development Officer of Revolution Medicines, Inc., filed Form 4 detailing open market sales executed on September 16, 2026. The sales involved a cumulative 341 shares of common stock for total proceeds of approximately $67,940.67.

Transaction Details

• Security: Common Stock
• Transactions:
  • 5 shares sold at an average price of $194.9589 ($974.79 total)
  • 336 shares sold at an average price of $199.3032 ($66,965.88 total)
• Weighted Average Price: ~$199.24 per share
• Total Transacted Shares: 341 shares
• Nature of Ownership: Direct
• Post-Transaction Beneficial Ownership: 52,868 shares (includes 52,350 RSUs and 209 shares acquired via the ESPP on May 31, 2026)

Market & Trading Significance

• Trading Significance: Low
• Context: The disposition was executed pursuant to a pre-established Rule 10b5-1 instruction letter adopted on June 13, 2026, explicitly aimed at covering tax withholding obligations stemming from the vesting of restricted stock units (RSUs).
• Takeaway: The small size of the transaction relative to the insider's total equity holdings (representing less than 1% of total holdings) combined with its nondiscretionary nature (sell-to-cover for taxes under Rule 10b5-1) indicates no signal regarding insider sentiment on company fundamentals.